CytomX Therapeutics (CTMX) Total Non-Current Liabilities (2014 - 2026)

CytomX Therapeutics (CTMX) has 11 years of Total Non-Current Liabilities data on file, last reported at $35.0 million in Q1 2026.

• Quarterly Total Non-Current Liabilities fell 49.47% year-over-year to $35.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $35.0 million (down 49.47% YoY) and the FY2025 annual result came in at $48.2 million, down 58.75% from the prior year.
• Total Non-Current Liabilities slipped to $35.0 million in Q1 2026, from $48.2 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $346.6 million in Q4 2022 to a low of $35.0 million in Q1 2026.
• A 5-year average of $171.0 million and a median of $172.4 million in 2024 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2023 — Total Non-Current Liabilities slipped 6.56% — and 2025, when it slumped 72.7%.
• Tracing CTMX's Total Non-Current Liabilities over 5 years: stood at $346.6 million in 2022, then retreated by 29.22% to $245.3 million in 2023, then plunged by 52.36% to $116.9 million in 2024, then tumbled by 58.75% to $48.2 million in 2025, then retreated by 27.39% to $35.0 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $35.0 million (Q1 2026), $48.2 million (Q4 2025), and $46.6 million (Q3 2025), per Business Quant data.